Subscribe to Search results

The Food and Drug Administration inspection regime for plasma centres commenced in the US.

Published on:

The Morbidity and Mortality Weekly Report reported that three people with haemophilia had contracted AIDS in the US.

Published on:

Alpha informed the Food and Drug Administration it would not be using plasma from hyperimmunised donors for factor concentrate manufacture.

Published on:

A memo from Dr John Hink of Cutter recorded his intention that remaining high titre plasma, dating from July 1982, would be processed in experimental products that would not be for human use.

Published on:

Pharmaceutical companies started excluding high risk donors (especially male homosexuals, intravenous drug users).

Published on:

A public meeting was held in Atlanta at the instigation of Centers for Disease Control to discuss AIDS.

Published on:

Alpha issued a press release warning of a real risk of AIDS from taking Factor 8 concentrates.

Published on:

Dr John Petricciani of the Food and Drug Administration sent a letter to all Licensed Manufacturers of Plasma Derivatives recommending excluding high risk plasma from blood products.

Published on:

The US Blood Products Advisory Committee discussed product recall and concluded it should be decided on a case-by-case basis.

Published on:

Notes on Transfusion by Ministry of Health warned of risks of transfusion.

Published on:

A parent of a Treloar's student provided consent for their son to take part in a DDAVP trial but asked for further information about this "other substance".

Published on:

In 1976 over 600,000 units of cryoprecipitate, just over 150,000 units of NHS Factor 8 and over 1,000,000 units of three different commercial concentrates were used at Treloar's.

Published on:

In 1977 cryoprecipitate and NHS factor concentrates were both used at Treloar's, as well as four commercial products.

Published on:

Blood Concentrate products were most probably first used at Treloar's after March 1969.

Published on:

In a letter to Dr Maycock, Dr Rainsford stated that the Treloar's students had not been adequately treated with AHG before he had arrived at the school.

Published on:

Dr Iain Frew, the home clinician of a Treloar's student, wrote to Dr Aronstam regarding the higher doses of cryoprecipitate provided by Treloar's.

Published on:

Dr Aronstam stated in a letter that the use of prophylaxis was a routine at Treloar's "in many clinical situations" and described the programme as "admittedly enthusiastic".

Published on:

Stephen Nicholls recollected that prophylaxis treatment was really pushed at Treloar's.

Published on:

Following two trials, Dr Aronstam recognised the potential where prophylaxis reduced the frequency of bleeding episodes and the potential danger of hyper-transfusion with blood products.

Published on:

Dr Swinburne (Leeds Haemophilia Centre) suggested that it was wise that the patient be treated with one product and Hemofil was recommended.

Published on: